Recombinant human EPO (rHuEPO, hereafter EPO) is widely prescribed for treating anemia in patients with advanced chronic kidney disease 2, as well as anemia associated with certain hematological disorders, primarily myelodysplastic syndromes and multiple myeloma 3, 4. Here, EPO is linked to AL amyloidosis.